What is Koru Med Sys's earnings per share (EPS)?

Koru Med Sys (KRMD) reported diluted earnings per share of $-0.06 for fiscal year 2025. This represents a 53.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Koru Med Sys Financials

KRMD

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Koru Med Sys (KRMD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 39/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Koru Med Sys has an operating margin of -7.2%, meaning the company retains $-7 of operating profit per $100 of revenue. This below-average margin results in a low score of 6/100, suggesting thin profitability after operating expenses. This is up from -19.2% the prior year.

Growth

Koru Med Sys's revenue surged 22.2% year-over-year to $41.1M, reflecting rapid business expansion. This strong growth earns a score of 70/100.

Leverage

Koru Med Sys carries a low D/E ratio of 0.65, meaning only $0.65 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 89/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Koru Med Sys's current ratio of 2.44 indicates adequate short-term liquidity, earning a score of 46/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

While Koru Med Sys generated $462K in operating cash flow, capex of $933K consumed most of it, leaving -$470K in free cash flow. This results in a low score of 22/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Koru Med Sys generates a -15.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is up from -36.1% the prior year.

Piotroski F-Score Neutral

4/9

Koru Med Sys passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.18x

For every $1 of reported earnings, Koru Med Sys generates $-0.18 in operating cash flow ($462K OCF vs -$2.6M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$41.1M

YoY+22.2%

5Y CAGR+11.2%

10Y CAGR+13.8%

Koru Med Sys generated $41.1M in revenue in fiscal year 2025. This represents an increase of 22.2% from the prior year.

EBITDA

-$2.2M

YoY+61.1%

Koru Med Sys's EBITDA was -$2.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 61.1% from the prior year.

Net Income

-$2.6M

YoY+56.5%

Koru Med Sys reported -$2.6M in net income in fiscal year 2025. This represents an increase of 56.5% from the prior year.

EPS (Diluted)

$-0.06

YoY+53.8%

Koru Med Sys earned $-0.06 per diluted share (EPS) in fiscal year 2025. This represents an increase of 53.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$470K

YoY+70.9%

Koru Med Sys generated -$470K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 70.9% from the prior year.

Cash & Debt

$8.9M

YoY-7.4%

5Y CAGR-20.1%

10Y CAGR+13.2%

Koru Med Sys held $8.9M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

46M

YoY+0.9%

5Y CAGR+1.4%

10Y CAGR+2.0%

Koru Med Sys had 46M shares outstanding in fiscal year 2025. This represents an increase of 0.9% from the prior year.

Margins & Returns

Gross Margin

62.3%

YoY-1.1pp

5Y CAGR+0.5pp

10Y CAGR+2.8pp

Koru Med Sys's gross margin was 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.1 percentage points from the prior year.

Operating Margin

-7.2%

YoY+11.9pp

5Y CAGR-2.0pp

10Y CAGR-17.4pp

Koru Med Sys's operating margin was -7.2% in fiscal year 2025, reflecting core business profitability. This is up 11.9 percentage points from the prior year.

Net Margin

-6.4%

YoY+11.6pp

5Y CAGR-1.4pp

10Y CAGR-13.1pp

Koru Med Sys's net profit margin was -6.4% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11.6 percentage points from the prior year.

Return on Equity

-15.5%

YoY+20.6pp

5Y CAGR-12.1pp

10Y CAGR-27.5pp

Koru Med Sys's ROE was -15.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 20.6 percentage points from the prior year.

Capital Allocation

R&D Spending

$4.4M

YoY-16.6%

5Y CAGR+27.6%

10Y CAGR+25.1%

Koru Med Sys invested $4.4M in research and development in fiscal year 2025. This represents a decrease of 16.6% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$933K

YoY-28.1%

5Y CAGR+0.3%

10Y CAGR+4.7%

Koru Med Sys invested $933K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 28.1% from the prior year.

KRMD Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$41.1M+22.2%	$33.6M+18.0%	$28.5M+2.2%	$27.9M+18.8%	$23.5M-2.8%	$24.2M
Cost of Revenue	$15.5M+26.1%	$12.3M+4.3%	$11.8M-5.7%	$12.5M+28.9%	$9.7M+5.2%	$9.2M
Gross Profit	$25.6M+20.0%	$21.3M+27.7%	$16.7M+8.7%	$15.4M+11.6%	$13.8M-7.8%	$14.9M
R&D Expenses	$4.4M-16.6%	$5.3M-8.4%	$5.7M+15.9%	$5.0M+100.4%	$2.5M+90.8%	$1.3M
SG&A Expenses	$23.4M+8.1%	$21.6M+6.2%	$20.4M-1.2%	$20.6M+15.4%	$17.9M+48.5%	$12.0M
Operating Income	-$3.0M+53.9%	-$6.4M+37.2%	-$10.3M+4.7%	-$10.8M-53.4%	-$7.0M-460.2%	-$1.3M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	$22K+656.7%	$3K-99.9%	$4.0M+297.0%	-$2.0M-11.8%	-$1.8M-10021.4%	-$18K
Net Income	-$2.6M+56.5%	-$6.1M+55.9%	-$13.7M-58.7%	-$8.7M-89.8%	-$4.6M-276.5%	-$1.2M
EPS (Diluted)	$-0.06+53.8%	$-0.13+56.7%	$-0.30-57.9%	$-0.19-90.0%	$-0.10-233.3%	$-0.03

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$10.9M+4.7%	$10.4M+2.0%	$10.2M+5.8%	$9.6M+9.0%	$8.8M+8.1%	$8.2M-3.0%	$8.4M+2.8%	$8.2M
Cost of Revenue	$4.1M-1.4%	$4.1M+11.3%	$3.7M+3.6%	$3.6M+9.6%	$3.3M+9.4%	$3.0M+1.5%	$3.0M-4.7%	$3.1M
Gross Profit	$6.8M+8.8%	$6.3M-3.3%	$6.5M+7.1%	$6.0M+8.7%	$5.6M+7.3%	$5.2M-5.4%	$5.5M+7.4%	$5.1M
R&D Expenses	$1.1M+22.7%	$933K-21.9%	$1.2M+7.2%	$1.1M0.0%	$1.1M-27.4%	$1.5M+35.2%	$1.1M-23.1%	$1.5M
SG&A Expenses	$6.0M+0.8%	$6.0M+11.3%	$5.4M-9.7%	$6.0M+2.3%	$5.8M+13.6%	$5.1M-3.6%	$5.3M-0.7%	$5.4M
Operating Income	-$547K+36.9%	-$868K-177.5%	-$313K+74.9%	-$1.2M+21.7%	-$1.6M+6.7%	-$1.7M-42.9%	-$1.2M+39.2%	-$2.0M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	-$150-100.9%	$17K	N/A	N/A	N/A	N/A	N/A
Net Income	-$487K+37.4%	-$778K-276.1%	-$207K+82.3%	-$1.2M+25.3%	-$1.6M+1.2%	-$1.6M-59.9%	-$989K+48.9%	-$1.9M
EPS (Diluted)	N/A	$0.02	$0.00-100.0%	$0.03	N/A	$0.03+50.0%	$0.02-50.0%	$0.04

KRMD Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$28.2M+3.6%	$27.2M-4.4%	$28.5M-32.8%	$42.3M+2.5%	$41.3M+3.4%	$39.9M
Current Assets	$20.0M+4.5%	$19.1M-5.5%	$20.3M-32.0%	$29.8M-20.1%	$37.3M-0.5%	$37.5M
Cash & Equivalents	$8.9M-7.4%	$9.6M-16.6%	$11.5M-34.0%	$17.4M-31.3%	$25.3M-7.3%	$27.3M
Inventory	$3.7M+31.2%	$2.8M-19.5%	$3.5M-45.6%	$6.4M+4.9%	$6.1M-10.6%	$6.8M
Accounts Receivable	$6.2M+8.6%	$5.7M+41.4%	$4.0M+13.7%	$3.6M-0.9%	$3.6M+39.6%	$2.6M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.2M+7.2%	$10.4M+28.3%	$8.1M-26.3%	$11.0M+129.7%	$4.8M+27.4%	$3.8M
Current Liabilities	$8.2M+13.8%	$7.2M+61.7%	$4.5M-36.0%	$7.0M+45.2%	$4.8M+30.7%	$3.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$17.0M+1.4%	$16.8M-17.4%	$20.4M-35.0%	$31.3M-14.2%	$36.5M+1.0%	$36.2M
Retained Earnings	-$32.0M-9.0%	-$29.4M-26.0%	-$23.3M-143.6%	-$9.6M-951.7%	-$910K-124.9%	$3.7M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$28.2M+4.0%	$27.1M+6.2%	$25.5M-6.2%	$27.2M0.0%	$27.2M-0.6%	$27.4M+0.3%	$27.3M-0.7%	$27.5M
Current Assets	$20.0M+2.9%	$19.4M+10.5%	$17.6M-7.5%	$19.0M-0.7%	$19.1M+1.1%	$18.9M-2.3%	$19.4M-0.6%	$19.5M
Cash & Equivalents	$8.9M+4.8%	$8.5M+5.1%	$8.1M-7.8%	$8.7M-8.8%	$9.6M+8.8%	$8.8M-15.8%	$10.5M-3.3%	$10.8M
Inventory	$3.7M-16.6%	$4.4M+11.7%	$3.9M+20.4%	$3.3M+16.9%	$2.8M-28.6%	$3.9M+51.7%	$2.6M-17.7%	$3.1M
Accounts Receivable	$6.2M+14.7%	$5.4M+9.8%	$4.9M-17.2%	$5.9M+4.0%	$5.7M+10.8%	$5.2M-11.7%	$5.8M+33.1%	$4.4M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$11.2M+4.8%	$10.6M+18.3%	$9.0M-17.3%	$10.9M+4.5%	$10.4M+7.7%	$9.7M+12.3%	$8.6M+2.6%	$8.4M
Current Liabilities	$8.2M+4.6%	$7.8M+29.5%	$6.1M-22.4%	$7.8M+8.3%	$7.2M+13.9%	$6.3M+23.1%	$5.1M+5.9%	$4.9M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$17.0M+3.5%	$16.5M-0.4%	$16.5M+1.1%	$16.3M-2.8%	$16.8M-5.2%	$17.7M-5.2%	$18.7M-2.2%	$19.1M
Retained Earnings	-$32.0M-1.5%	-$31.5M-2.5%	-$30.8M-0.7%	-$30.5M-4.0%	-$29.4M-5.6%	-$27.8M-6.0%	-$26.2M-3.9%	-$25.2M

KRMD Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$462K+244.6%	-$320K+93.5%	-$4.9M+9.5%	-$5.4M-25.1%	-$4.3M-481.1%	-$743K
Capital Expenditures	$933K-28.1%	$1.3M+65.7%	$783K-71.6%	$2.8M+697.6%	$346K-62.4%	$921K
Free Cash Flow	-$470K+70.9%	-$1.6M+71.5%	-$5.7M+30.5%	-$8.2M-75.0%	-$4.7M-180.4%	-$1.7M
Investing Cash Flow	-$950K+28.8%	-$1.3M-63.6%	-$815K+70.9%	-$2.8M-665.1%	-$366K+64.7%	-$1.0M
Financing Cash Flow	-$221K+10.9%	-$249K-13.6%	-$219K-178.3%	$279K-89.7%	$2.7M-88.4%	$23.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$1.1M+1572.5%	$65K+114.2%	-$460K-93.9%	-$237K-125.3%	$940K+201.7%	-$924K-8251.3%	$11K+103.3%	-$347K
Capital Expenditures	$408K+677.0%	$52K+82.1%	$29K-93.5%	$443K+1117.8%	-$44K-104.0%	$1.1M+771.9%	$124K-6.6%	$133K
Free Cash Flow	$687K+5195.4%	$13K+102.7%	-$489K+28.2%	-$681K-176.0%	$896K+144.6%	-$2.0M-1677.4%	-$113K+76.5%	-$480K
Investing Cash Flow	-$422K-703.4%	-$52K-82.1%	-$29K+93.6%	-$447K-980.7%	$51K+104.6%	-$1.1M-642.2%	-$149K-11.6%	-$133K
Financing Cash Flow	-$265K-166.8%	$396K+306.5%	-$192K-19.4%	-$161K+25.5%	-$216K-157.6%	$374K+266.3%	-$225K-23.6%	-$182K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

KRMD Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	62.3%-1.1pp	63.4%+4.8pp	58.6%+3.5pp	55.1%-3.5pp	58.6%-3.2pp	61.8%
Operating Margin	-7.2%+11.9pp	-19.2%+16.8pp	-36.0%+2.6pp	-38.6%-8.7pp	-29.9%-24.7pp	-5.2%
Net Margin	-6.4%+11.6pp	-18.0%+30.1pp	-48.2%-17.1pp	-31.1%-11.6pp	-19.4%-14.4pp	-5.0%
Return on Equity	-15.5%+20.6pp	-36.1%+31.4pp	-67.5%-39.9pp	-27.7%-15.2pp	-12.5%-9.2pp	-3.4%
Return on Assets	-9.3%+12.9pp	-22.3%+26.0pp	-48.3%-27.8pp	-20.5%-9.4pp	-11.1%-8.0pp	-3.0%
Current Ratio	2.44-0.2	2.66-1.9	4.55+0.3	4.28-3.5	7.79-2.4	10.23
Debt-to-Equity	0.65+0.0	0.62+0.2	0.40+0.0	0.35+0.2	0.13+0.0	0.10
FCF Margin	-1.1%+3.7pp	-4.8%+15.1pp	-19.9%+9.4pp	-29.3%-9.4pp	-19.9%-13.0pp	-6.9%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	62.6%+2.4pp	60.2%-3.3pp	63.5%+0.8pp	62.7%-0.2pp	62.9%-0.5pp	63.4%-1.6pp	65.0%+2.7pp	62.3%
Operating Margin	-5.0%+3.3pp	-8.3%-5.3pp	-3.1%+9.8pp	-12.9%+5.1pp	-18.0%+2.8pp	-20.8%-6.7pp	-14.1%+9.8pp	-23.9%
Net Margin	-4.5%+3.0pp	-7.5%-5.5pp	-2.0%+10.1pp	-12.1%+5.6pp	-17.7%+1.7pp	-19.3%-7.6pp	-11.7%+11.9pp	-23.6%
Return on Equity	-2.9%+1.9pp	-4.7%-3.5pp	-1.3%+5.9pp	-7.1%+2.1pp	-9.3%-0.4pp	-8.9%-3.6pp	-5.3%+4.8pp	-10.1%
Return on Assets	-1.7%+1.1pp	-2.9%-2.1pp	-0.8%+3.5pp	-4.3%+1.4pp	-5.7%+0.0pp	-5.8%-2.1pp	-3.6%+3.4pp	-7.0%
Current Ratio	2.44-0.0	2.48-0.4	2.91+0.5	2.44-0.2	2.66-0.3	2.99-0.8	3.77-0.2	4.01
Debt-to-Equity	0.650.0	0.65+0.1	0.54-0.1	0.67+0.0	0.62+0.1	0.54+0.1	0.46+0.0	0.44
FCF Margin	6.3%+6.2pp	0.1%+4.9pp	-4.8%+2.3pp	-7.1%-17.2pp	10.1%+34.7pp	-24.5%-23.2pp	-1.3%+4.5pp	-5.9%

Similar Companies

Utah Med Prods UTMD

$200.2M

ANTERIS TECHNOLOGIES GLOBAL AVR

$534.8M

Infusystem Hld INFU

$188.0M

NYXOAH S A NYXH

$138.4M

Microbot Med Inc MBOT

$159.2M

Frequently Asked Questions

What is Koru Med Sys's annual revenue?

Koru Med Sys (KRMD) reported $41.1M in total revenue for fiscal year 2025. This represents a 22.2% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Koru Med Sys's revenue growing?

Koru Med Sys (KRMD) revenue grew by 22.2% year-over-year, from $33.6M to $41.1M in fiscal year 2025.

Is Koru Med Sys profitable?

No, Koru Med Sys (KRMD) reported a net income of -$2.6M in fiscal year 2025, with a net profit margin of -6.4%.

What is Koru Med Sys's EBITDA?

Koru Med Sys (KRMD) had EBITDA of -$2.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Koru Med Sys's gross margin?

Koru Med Sys (KRMD) had a gross margin of 62.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Koru Med Sys's operating margin?

Koru Med Sys (KRMD) had an operating margin of -7.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Koru Med Sys's net profit margin?

Koru Med Sys (KRMD) had a net profit margin of -6.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Koru Med Sys's return on equity (ROE)?

Koru Med Sys (KRMD) has a return on equity of -15.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Koru Med Sys's free cash flow?

Koru Med Sys (KRMD) generated -$470K in free cash flow during fiscal year 2025. This represents a 70.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Koru Med Sys's operating cash flow?

Koru Med Sys (KRMD) generated $462K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Koru Med Sys's total assets?

Koru Med Sys (KRMD) had $28.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Koru Med Sys's capital expenditures?

Koru Med Sys (KRMD) invested $933K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Koru Med Sys spend on research and development?

Koru Med Sys (KRMD) invested $4.4M in research and development during fiscal year 2025.

How many shares does Koru Med Sys have outstanding?

Koru Med Sys (KRMD) had 46M shares outstanding as of fiscal year 2025.

What is Koru Med Sys's current ratio?

Koru Med Sys (KRMD) had a current ratio of 2.44 as of fiscal year 2025, which is generally considered healthy.

What is Koru Med Sys's debt-to-equity ratio?

Koru Med Sys (KRMD) had a debt-to-equity ratio of 0.65 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Koru Med Sys's return on assets (ROA)?

Koru Med Sys (KRMD) had a return on assets of -9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Koru Med Sys's Piotroski F-Score?

Koru Med Sys (KRMD) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Koru Med Sys's earnings high quality?

Koru Med Sys (KRMD) has an earnings quality ratio of -0.18x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Koru Med Sys?

Koru Med Sys (KRMD) scores 39 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.